password
username
Sponsored by CakeMail, an email marketing software
Newsletter preview

When you registered with www.MDLinx.com, you subscribed to this newsletter.
Please add this email address (newsletter@newstwo.mdlinx.com) to your address book to ensure safe delivery.
 
Marketing/Media/ROI Daily Newsletter
Tuesday, March, 27 2007
Sponsor
Home | News | CME | Conferences | Resource Center | Job Center | Help
TODAY'S ARTICLES How do we make this list? [click here]
Sponsor
Sponsor
Sponsor
Sponsor
Sponsor
GE Healthcare Achieves #1 Worldwide Market Share Position in Compact Ultrasound Industry in 2006
GE Healthcare became the world market share leader in the compact ultrasound industry in 2006, as cited in a recent industry report issued by Klein Biomedical Consultants, an internationally recognized source of ultrasound market and trends. GE was the market leader with a 43 percent share, according to the report...[more...] Free Full Text   
Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
Mylan Laboratories Inc. announced its latest first to market generic product with the launch of Ciprofloxacin Extended-release (ER) Tablets in 500mg and 1000mg strengths. Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for both strengths of Ciprofloxacin ER Tablets, March 22 and began shipping immediately that day. Ciprofloxacin ER is the latest Mylan generic product that leverages Mylan's expertise in extended release formulations...[more...] Free Full Text   
Victory Pharma, Inc. Sales Force Expansion Signifies Growth of Its US Commercial Operations
Victory Pharma, Inc. a specialty pharmaceutical company with a portfolio of pain related products, announced that it has completed its sales force expansion. The sales force promotes the Company's unique and innovative line of prescription pain products including recently acquired marketing rights for NAPRELAN...[more...] Free Full Text   
Protox Outlines Milestones for 2007
Protox TM Therapeutics Inc. announced the company's key milestones for the coming year that will help position the company as a leader in targeted therapeutics for cancer and other proliferative diseases. They include the completion of a Phase I study in prostate cancer, the initiation of a Phase I study in benign prostatic hyperplasia and the initiation of a Phase IIb study in brain cancer...[more...] Free Full Text   
AstraZeneca expects strong sales growth in China
AstraZeneca expects sales in China to grow more than 20 pct annually in the 2007-2010 period, the Shanghai Daily reported, citing James Ward-Lilley, president of AstraZeneca China.To develop drugs for the Chinese market, AstraZeneca said that it had chosen Shanghai's Zhangjiang High-Tech Industrial Park as a base for its research and development effort, part of plans to invest up to 100 mln usd in R&D in China...[more...]
PharmiWeb, 03/26/07
Free Full Text   
Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone
In response to an announcement by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company's Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-month pediatric exclusivity period that expires in September, 2007...[more...] Free Full Text   
Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc.
Cubist Pharmaceuticals, Inc. announced that it has entered into a license agreement with Merck & Co., Inc. for the development and commercialization of CUBICIN (daptomycin for injection) in Japan. Merck will develop and commercialize CUBICIN through its wholly-owned subsidiary, Banyu Pharmaceutical Co., Ltd. With this agreement in Japan, Cubist has secured an excellent partner for CUBICIN, its first-in-class lipopeptide antibiotic, and now has a full complement of partners ready to commercialize CUBICIN around the world. Cubist commercializes CUBICIN in the United States...[more...] Free Full Text   
Boston Scientific iLab(TM) System Hits Record Sales
Boston Scientific Corporation announced that worldwide sales of its iLab(TM) Ultrasound Imaging (IVUS) System have passed the 300 unit mark in just nine months since launch of the system in May of 2006. This is double the number of sales realized by the Galaxy(2)(TM) Imaging System, the predecessor to the iLab System and represents a significant increase in market penetration for the company's IVUS technology...[more...] Free Full Text   
GSK Announces Nationwide Availability of Once-A-Day COREG CR(TM) for the Treatment of Three Key Cardiovascular Conditions
GlaxoSmithKline announced that Coreg CR(TM) (carvedilol phosphate) extended- release capsules, a once-a-day beta-blocker, is now available at pharmacies nationwide. COREG CR is FDA-approved to treat three cardiovascular conditions: High blood pressure, also known as hypertension. A heart attack that has reduced how well the heart pumps (known medically as post-myocardial infarction left ventricular dysfunction). Mild to severe heart failure...[more...] Free Full Text   
Cambridge Heart Announces Co-Marketing Agreement with St. Jude Medical and a $12.5 Million Equity Investment
Cambridge Heart, Inc., announced a three-year exclusive sales and marketing agreement with St. Jude Medical, Inc., under which St. Jude Medical will be responsible for marketing Cambridge Heart's HearTwave II Microvolt T-Wave Alternans System and sensors to cardiologists and electrophysiologists in North America. Cambridge Heart's sales force will continue to market the HearTwave II to internal medicine and primary care practices. Alternans testing is designed to allow physicians to identify patients who are at increased risk of Sudden Cardiac Death (SCD)...[more...] Free Full Text   
[view more articles]
Sponsor
Hot Topic of the Day
Dark Chocolate may help lower the risk of Cardiovascular disease

A study out of  the Yale Prevention Research Center in Connecticut has found that the cocoa in dark chocolate may be able to boost the function of endothelial cells that line the inside of blood vessels. Cocoa contains a group of antioxidant compounds called flavonoids which are also found in fruits and vegetables, wine and green tea. The action of the flavonoids on the endothelial cells is what may help decrease the risk of cardiovascular disease.

The study included 45 healthy people which were divided into three groups that ate either eight ounces of cocoa without sugar; cocoa with sugar; or a placebo. They also underwent endothelial function testing using a high frequency ultrasound to measure flow mediated dilation (FMD). They found that the FMD improved significantly in 2.4% of the group who consumed cocoa with no sugar, and 1.5% percent of those who ate cocoa with sugar.  There was a 0.8% percent decrease in FMD in the group that ate the placebo.

Researchers believe that the significant improvement in endothelial function seen in this study could be further investigated in a long-term, randomized clinical trial.  They state that at this time they do not suggest making dark chocolate a  part of someone's daily routine, but only that we start to explore what cardiovascular benefits flavonoid-rich foods might offer.


MDLinx offers a new hot topic every day
[Past Hot Topics]
Sponsor
More Articles, by Subspecialty
Biotechnology

Conferences/Meetings

Drug Approvals

Drug Trials

Execs on the Move

Financial Reports

M&A/Partnerships

Marketing/Media/ROI

Medical Devices/Products

Physician/Patient Trends

Popular Press

Regulatory Issues

Research & Development

Top Articles of the Week
GE Healthcare Achieves #1 Worldwide Market Share Position in Compact Ultrasound Industry in 2006
[more...]
Mylan Announces Another First to Market With the Launch of Ciprofloxacin Extended-Release Tablets
[more...]
Victory Pharma, Inc. Sales Force Expansion Signifies Growth of Its US Commercial Operations
[more...]
Protox Outlines Milestones for 2007
Protox TM Therapeutics Inc. announced the company's key milestones for...[more...]
[view more articles]
MDLinx, Inc.
1232 22nd St, NW, Suite 200
Washington, DC 20037
Tel: 202.293.2288
Fax: 202.293.1690
UPDATE YOUR ACCOUNT SETTINGS
PRIVACY POLICY
Sponsor
When you signed up for MDLinx you requested this email be sent to you. To manage your newsletters and alert please login to your MDLinx account at:Login and click Manage Newsletters. If you do not wish to receive this newsletter, click here to ***: *** Me
? 2007, MDLinx, Inc.
MDLinx considers the privacy of its users to be of utmost importance and works to protect it. MDLinx uses personal user information for internal purposes only. We will not sell or share your information with outsiders. For comprehensive information about the steps that MDLinx takes to respect your privacy please read our Privacy Policy:
This email has been sent by MDLinx, Inc.
1232 22nd Street NW
Washington, DC 20037
Tel: +1.202.293.2288
Fax: +1.202.293.1690